Adovate Receives 2026 Innovative Employers Award
Charlottesville, VA – October 2, 2026 – Adovate, LLC (“Adovate” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics targeting the adenosine receptors, today announced that it has been named a 2026 Innovative Employer and Top Employer for Interns by the Virginia Economic Development Partnership (VEDP). Adovate is among a select group of employers across statewide and regional categories recognized for their established programs with longstanding support for interns’ career readiness.
The full list of honorees is available in VEDP’s announcement.
The recognition follows the completion of Adovate’s most recent summer internship program in 2026, which welcomed University of Virginia undergraduates in roles spanning laboratory research, artificial intelligence, business strategy, and company operations. Adovate’s program is supported in part through VEDP’s InternshipsVA Program and the CvilleBioHub Charlottesville Internship Program (CHIP).
“We are honored that VEDP has named Adovate a 2026 Innovative Employer,” said Uday Gupta, CFO/COO of Adovate. “This recognition belongs to our interns, who brought curiosity and initiative from day one, and to the team members who invested their time in mentoring them. Programs like InternshipsVA and CHIP make it easier for companies of every size to offer paid internships. We encourage other Virginia employers, especially in life sciences, to take advantage of these resources.”
About Adovate, LLC
Adovate is a biopharmaceutical company dedicated to inventing and developing best-in-class drug candidates targeting adenosine receptors. Founded in Charlottesville, Virginia, Adovate is at the forefront of novel drug discovery, focusing on adenosine receptor-modulating therapies for respiratory conditions, infectious diseases, cancer, non-opioid pain reduction, and immunological disorders, among others. The Company is actively collaborating with research institutions such as the University of Virginia, Virginia Tech, and the Medical College of Wisconsin to advance its therapeutics pipeline. Learn more at www.adovate.com.
Forward Looking Statements
This communication contains certain “forward-looking statements” within the meaning of applicable securities laws. These statements are based on current expectations, assumptions, and projections and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Forward-looking statements include, among others, statements regarding Adovate’s plans to expand its internship program, continue collaborations with academic and workforce development partners, and advance the development of its therapeutic pipeline. Words such as “expects,” “plans,” “intends,” “believes,” “anticipates,” “may,” “will,” “could,” “should,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements speak only as of the date they are made, and Adovate undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.
FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations:
ir@adovate.com
Media Relations:
media@adovate.com